Logo
x

Search

Subscribe Now

Corcept Therapeutics

Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism

Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism

  • January 1, 2025
Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)

Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)

  • April 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.